2023-510171-59-00已完成1 期
Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the Aerochamber Plus® spacer, in healthy volunteers.
Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A.1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年6月17日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years(18-64 Years)
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
- GLOBAL CLINICAL DEVELOPMENT
Scientific
Chiesi Farmaceutici S.p.A.
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the AeroChamber Plus® spacer, in healthy volunteers.Asthma2024-514247-28-00Chiesi Farmaceutici S.p.A.90
已完成
1 期
A research study of a new medicine (NNC0650-0013) in healthy men2023-506134-79-00Novo Nordisk A/S60
招募中
1 期
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.2025-523587-20-00Gruenenthal GmbH24
已完成
1 期
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR2023-507667-19-00Novartis Pharma AG24
已完成
1 期
A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes2023-506117-22-00Celgene Corp., Celgene Corp.153
